| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 07/27/2006 | WO2006078782A2 Compositions containing agm cells and methods of use thereof |
| 07/27/2006 | WO2006078640A2 Alterations utilizing nanoparticles |
| 07/27/2006 | WO2006077675A1 Fibrosis inhibitor for implanted organ |
| 07/27/2006 | WO2006077456A1 Oral administration of therapeutic agent coupled to transporting agent |
| 07/27/2006 | WO2006077410A1 Method of treatment by administration of rna |
| 07/27/2006 | WO2006077409A1 Method of genotypically modifying cells by administration of rna |
| 07/27/2006 | WO2006042147A3 Large-scale production of recombinant transmembrane and cytosolic proteins |
| 07/27/2006 | WO2005110459A3 Method of inducing immunity against stratum corneum chymotrytic enzyme |
| 07/27/2006 | WO2005102038A3 Expression of polypeptides in rod outer segment membranes |
| 07/27/2006 | WO2005020902A3 Compositions and methods for treating and diagnosing irritable bowel syndrome |
| 07/27/2006 | WO2004106360A3 Viral vectors with improved properties |
| 07/27/2006 | WO2004091479A3 Gene amplification and overexpression in cancer |
| 07/27/2006 | US20060168670 identification of new gene families that are differentially expressed in cancerous human tissues compared to normal human tissues; useful as diagnostic agents or markers to detect cancer or to differentiate carcinoma from normal tissue in a sample; nucleotide sequence |
| 07/27/2006 | US20060168667 Minibrain homologous proteins involved in the regulation of energy homeostasis |
| 07/27/2006 | US20060166924 Gene therapeutics |
| 07/27/2006 | US20060166923 Immune stimulating composition comprising bacterial chromosomal DNA fragments having methylated CpG sequences and non-toxic lipopolysaccharides |
| 07/27/2006 | US20060166922 Polynucleotides targeted against the extended 5'-UTR region of argininosuccinate synthase and uses thereof |
| 07/27/2006 | US20060166921 RNAi modulation of RSV and therapeutic uses thereof |
| 07/27/2006 | US20060166920 Oligonucleotide based therapeutics |
| 07/27/2006 | US20060166919 administering by ocular injection to the eye of a patient, for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression, an effective amount of an interfering RNA consisting of a length of 21 to 49 nucleotides; sense and antisense nucleotide sequences |
| 07/27/2006 | US20060166918 chemically modified oligonucleotides; double stranded iRNA agent; comprising a cholesterol moiety; increased stability in a biological sample |
| 07/27/2006 | US20060166917 Differentiation and/or proliferation modulating agents and uses therefor |
| 07/27/2006 | US20060166916 Composite polynucleic acid therapeutics |
| 07/27/2006 | US20060166915 Human coagulation factor VII polypeptides |
| 07/27/2006 | US20060166914 Method of nucleic acid infusion |
| 07/27/2006 | US20060166913 Process for producing sirna |
| 07/27/2006 | US20060166912 Use of cytochrome p450 enzyme cyp2w1 as a drug target for cancer theraphy |
| 07/27/2006 | US20060166911 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a (pde11a) |
| 07/27/2006 | US20060166910 Rna-interference by single-stranded rna molecules |
| 07/27/2006 | US20060166909 Oligonucleotide inhibitors of mbd2/dna demethylase and uses thereof |
| 07/27/2006 | US20060166908 Nucloeside analogues and oligonucleotide derivative comprising nucleotide analogue thereof |
| 07/27/2006 | US20060166889 Chimeric peptides that facilitate the transport of insulin across biological membranes that have a first domain having a specific translocation sequence and a second domain having at least a biologically active portion of an insulin polypeptide; treatment of diabetes |
| 07/27/2006 | US20060166887 recruiting neurons to the brain, and treating a neurodegenerative condition by injecting nucleic acid construct intraventricularly into subject's brain; Huntington's Disease |
| 07/27/2006 | US20060166881 Membrane-permeant peptide complexes for treatment of sepsis |
| 07/27/2006 | US20060166879 Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders |
| 07/27/2006 | US20060166878 treating a disease or disorder/condition associated with VEGF-induced neovascularization or angiogenesis; for topical application to the skin or to the eye |
| 07/27/2006 | US20060166876 Delocalization molecules and use thereof |
| 07/27/2006 | US20060166873 Preventive/remedy for arteriosclerosis |
| 07/27/2006 | US20060166864 Methods for modulating telomerase activity |
| 07/27/2006 | US20060166363 Modified baculovirus expression system for production of pseudotyped rAAV vector |
| 07/27/2006 | US20060166345 Method of inactivating enveloped viruses in a viral preparation of non-enveloped viruses |
| 07/27/2006 | US20060166318 Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
| 07/27/2006 | US20060166274 G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same |
| 07/27/2006 | US20060166255 Methods of using 48149, a human Aminopeptidase family member |
| 07/27/2006 | US20060166225 Methods and compositions for polypeptide engineering |
| 07/27/2006 | US20060166220 having apoptotic activity; exhibited anti-proliferative activity when expressed in transformed cells |
| 07/27/2006 | US20060166217 Genetic marker for coronary artery disease |
| 07/27/2006 | US20060166208 Induction of the mitochondrial permeability transition |
| 07/27/2006 | US20060166198 Providing a first population of single-stranded polynucleotide molecules and a second population of single-stranded polynucleotide molecules, carrying out reaction for digesting, contacting polynucleotide fragments generated from plus strands with fragments generated from the minus strands, amplifying |
| 07/27/2006 | US20060166194 Diagnosis and treatment of cancer |
| 07/27/2006 | US20060165810 Controlled release from block co-polymer worm micelles |
| 07/27/2006 | US20060165805 Magnetic pole matrices useful for tissue engineering and treatment of disease |
| 07/27/2006 | US20060165773 Gene therapy of tumors using non-viral delivery system |
| 07/27/2006 | US20060165768 Phosphoramide type cationic lipid compounds such as 3-[[bis(tetradecyloxy)phosphoryl](methyl)amino]-N,N,N-trimethyl-propanaminium iodide; use as nonviral vectors for gene transfer |
| 07/27/2006 | US20060165726 Remedies with the use of hollow protein nanoparticles presenting growth factor or the like |
| 07/27/2006 | US20060165713 Vaccine |
| 07/27/2006 | US20060165707 Substances |
| 07/27/2006 | US20060165699 Use of specified tcf target genes to identify drugs for the treatment of cancer in particular colorectal cancer in which tcf/ss-cateini/wnt signalling plays a central role |
| 07/27/2006 | US20060165689 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 |
| 07/27/2006 | US20060165684 T-cell immune response cDNA 7 (TIRC7) antagonist; rheumatoid arthritis; comprising all three complementarity determining regions (CDRs) of the VH and all three complementarity determining regions (CDRs) of the VL variable regions; inhibiting proliferation of peripheral blood mononuclear cells |
| 07/27/2006 | US20060165679 Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 2 (vpac2) |
| 07/27/2006 | US20060165668 Genetically modified tumor cells as cancer vaccines |
| 07/27/2006 | US20060165667 Novel methods, compositions and devices for inducing neovascularization |
| 07/27/2006 | US20060165666 Hemangioblast progenitor cells |
| 07/27/2006 | US20060165665 Immunomodulation using altered dendritic cells |
| 07/27/2006 | US20060165664 Method of inducing an enhanced immune response against hiv |
| 07/27/2006 | US20060165660 DNA preparation comprising a DNA, proteins and endotoxins; gene therapy; cystic fibrosis |
| 07/27/2006 | US20060165659 detecting a reduction in gene copy number, by determining gene mutational status, or by detecting a reduction in the RNA transcribed from these genes; inhibition of neoplastic or tumorigenic growth of cancers such as chronic lymphocytic leukemia or prostate cancer cells |
| 07/27/2006 | US20060165658 Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
| 07/27/2006 | US20060165657 Method for delivery of cosmetic by topical application |
| 07/27/2006 | US20060165656 Medicinal preparation having chemotherapeutic encapsulated therein |
| 07/27/2006 | US20060163393 Apparatus and method for automatically defibering and extracting kraft pulp from old corrugated cardboard |
| 07/27/2006 | DE102005003207A1 Lentivirales Gentransfersystem für Ribozym-vermittelte RNA-Reparatur The lentiviral gene transfer system for ribozyme-mediated RNA repair |
| 07/27/2006 | DE102005002353A1 Use of receptor multimerization epitope (RME) of advanced glycation end product receptor (AGER) as immunogen, useful for preparing antibodies for diagnosis and treatment of e.g. spinal injuries or diabetic complications |
| 07/27/2006 | CA2595704A1 Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids |
| 07/27/2006 | CA2595528A1 Method of treatment by administration of rna |
| 07/27/2006 | CA2595523A1 Method of genotypically modifying cells by administration of rna |
| 07/27/2006 | CA2594629A1 Fibrosis inhibitor for implanted organ |
| 07/27/2006 | CA2563538A1 Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations |
| 07/27/2006 | CA2562685A1 Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety |
| 07/26/2006 | EP1683863A2 A method for enhancing neurone survival and agents useful for same |
| 07/26/2006 | EP1683858A2 Viral preparations, vectors, immunogens, and vaccines |
| 07/26/2006 | EP1683811A2 Compositions and methods for the treatment of tumors |
| 07/26/2006 | EP1683807A1 Combination products for use in antitumoral treatment, comprising an antibody capable of inhibiting the activity of CSF-1 |
| 07/26/2006 | EP1683527A1 Method of inhibiting secretase activity |
| 07/26/2006 | EP1682682A2 Compositions and methods for modulating c-rel-dependent cytokine production |
| 07/26/2006 | EP1682663A2 The use of eukaryotic genes affecting spindle formation or microtubule function during cell division for diagnosis and treatment of proliferative diseases |
| 07/26/2006 | EP1682579A1 Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| 07/26/2006 | EP1682574A2 The use of eukaryotic genes affecting chromatin separation for diagnosis and treatment of proliferative diseases |
| 07/26/2006 | EP1682573A2 The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases |
| 07/26/2006 | EP1682565A1 Iap nucleobase oligomers and oligomeric complexes and uses thereof |
| 07/26/2006 | EP1682504A2 Hydroxy piperidine derivatives to treat gaucher disease |
| 07/26/2006 | EP1682187A2 Oligoribonucleotides for the treatment of undesired skin and hair pigmentation due to rna interference |
| 07/26/2006 | EP1682173A2 Listeria-based epha2 vaccines |
| 07/26/2006 | EP1682171A2 Compositions and methods of treating neurological diseases |
| 07/26/2006 | EP1682134A2 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
| 07/26/2006 | EP1682073A2 Method and antisense composition for selective inhibition of hiv infection in hematopoietic cells |
| 07/26/2006 | EP1681988A2 Method for diagnosis and treatment of pulmonary disorders |
| 07/26/2006 | EP1390543B1 New polynucleotides and polypeptides of the ifnalpha-17 gene |
| 07/26/2006 | EP1381686B1 Inactivation of genes of the mep pathway |